

METHOD AND PHARMACEUTICAL COMPOSITION FOR TREATMENT OF SKIN NEOPLASM

BACKGROUND OF THE INVENTION

1. Field of the Invention

The present invention relates to a method and pharmaceutical composition for the treatment of skin neoplasm, and more particularly to the novel uses of arsenic trioxide for treating skin neoplasm.

2. Description of Related Art

Arsenic trioxide has been considered to be both a poison and a drug for a long time in both Western and Chinese medical practices. Because of the known carcinogenic effect of arsenic trioxide, arsenic trioxide was only used in Western medicine to treat tropical diseases such as African trypanosomiasis. In the latter part of the nineteenth century, arsenic trioxide was used frequently in attempts to treat diseases of the blood in the West. In traditional Chinese medicine, arsenic trioxide has been used to treat tooth marrow diseases, psoriasis, syphilis and rheumatosis.

In recent years, arsenic trioxide was reported as a treatment for leukemic patients with markedly reduced white blood cell count. Further reports described that arsenic trioxide can treat acute promyelocytic leukemia (Blood, 88(3): 1052-1061, 1996; European Journal of Cancer, 35(8): 1258-1263, 1999; and The New England Journal of Medicine, 339(19): 1341-1348, 1998).

Although arsenic trioxide is well known to be both a poison and a carcinogenic agent, many people are studying the use of arsenic trioxide in medical treatment.

1 SUMMARY OF THE INVENTION

2 An aspect of the present invention is to provide a pharmaceutical
3 composition for the treatment of skin neoplasm. The pharmaceutical
4 composition comprises a therapeutically effective amount of arsenic trioxide and
5 a pharmaceutically acceptable carrier.

6 Another aspect of the present invention is to provide a method for
7 treating skin neoplasm in a human. The method comprises administering to a
8 human in need of treatment for skin neoplasm a therapeutically effective amount
9 of a pharmaceutical composition comprising arsenic trioxide.

10 Further benefits and advantages of the present invention will become
11 apparent after a careful reading of the detailed description with appropriate
12 reference to the accompanying drawings.

13 BRIEF DESCRIPTION OF THE DRAWINGS

14 Fig. 1 is a graph showing anti-tumor therapeutic efficacy of arsenic
15 trioxide administered to the wounded skin of mice with time; and

16 Fig. 2 is a graph showing anti-tumor therapeutic efficacy of arsenic
17 trioxide administered to the skin of mice with time.

18 DETAILED DESCRIPTION OF THE INVENTION

19 The term "therapeutically effective amount" as used herein means a
20 nontoxic but sufficient amount of an active agent to provide the desired
21 therapeutic effect.

22 The term "administered topically " as used herein is used in its
23 conventional sense to mean delivery of a topical drug of a pharmacologically
24 active agent to the skin, as in, for example, the treatment of various skin

1 neoplasm. Topical drug administration provides a local rather than a systemic
2 effect.

3 The term "carrier" as used herein refers to carrier material suitable for
4 topical drug administration. Carriers useful herein include any such materials
5 known in the art, which are nontoxic and do not interact with other components
6 of the composition in a deleterious manner.

7 Arsenic trioxide is white or transparent non-crystal lumps or crystal,
8 difficult to dissolve in water, having a sweet taste and is poison. Arsenic trioxide
9 is usually used in manufacturing glass or enamel materials.

10 In a preferred embodiment of the present invention, the treatment of
11 subcutaneous tumors in animal experiments with arsenic trioxide obviously
12 suppressed the tumor growth whether the tumor was incised or not. Arsenic
13 trioxide employed according to the present invention can be used to treat skin
14 neoplasm. Preferably, arsenic trioxide employed according to the present
15 invention can be used for treatment of subcutaneous tumors, primary skin cancer,
16 melanomatous cancer or metastatic cutaneous cancer. The primary skin cancer
17 includes basic cell carcinoma, squamous cell carcinoma and Merkel cell
18 carcinoma.

19 The present invention provides a pharmaceutical composition, a dosage
20 form and a method for the treatment of skin neoplasm. The pharmaceutical
21 composition for the treatment of skin neoplasm in accordance with the present
22 invention comprises a therapeutically effective amount of arsenic trioxide and a
23 pharmaceutically acceptable carrier. The method for treating of skin neoplasm in
24 accordance with the present invention comprises administering to a human in

1 need thereof a therapeutically effective amount of a pharmaceutical composition
2 comprising arsenic trioxide.

3 In a preferred embodiment of the present invention, a dosage form
4 suitable for topical administration which comprises the foregoing composition.
5 Preferably, the dosage form comprises viscid substance for preventing arsenic
6 trioxide from spreading in the air. The viscid dosage form can prevent patient or
7 medical personnel from inhaling arsenic trioxide. Preferably, the viscid
8 substance is starch or polymer. More preferably, the polymer is polyarylic acid,
9 carbomer, hydroxyethyl cellulose, chitosan, hydroxypropyl cellulose,
10 hydroxypropyl methylcellulose, sodium carboxymethylcellulose, polyvinyl
11 alcohol or a mixture thereof.

12 In a preferred embodiment of the present invention, the dosage form is
13 in the form of a gel. Preferably, the gel comprises by weight based on the total
14 weight of the gel

15 0.05 % arsenic trioxide;
16 1.5 % carbomer 940;
17 5.5 % PEG; and
18 0.125 % propyl paraben.

19 In an embodiment of the present invention, arsenic trioxide can be used
20 as the active ingredient combination with a pharmaceutical carrier according to
21 conventional pharmaceutical techniques. The carrier may include a wide variety
22 of forms depending on the form of preparation desired for administration, e.g.,
23 topical administration. In preparing the compositions for topical administration
24 dosage form, any of the usual pharmaceutical media may be employed, e.g.,

1 water, glycols, oils, alcohols, flavoring agents, preservatives, coloring agents,
2 and the like.

3 The therapeutically effective amount of arsenic trioxide for specific skin
4 neoplasm will vary with the severity of the condition to be treated and the route
5 of administration. The therapeutically effective amount of arsenic trioxide will
6 also vary according to the age, body weight, condition and response of the
7 individual patient. In general, the therapeutically effective amount of arsenic
8 trioxide for the conditions described herein are generally from 0.01 to 1 mg/g of
9 the composition administered topically. A preferred therapeutically effective
10 amount of arsenic trioxide is from 0.1 to 0.5 mg/g of the composition.

11 The composition may be in any form suitable for application to the body
12 surface and may comprise, for example, a cream, lotion, solution, suspension,
13 gel, ointment, paste, balm, spray, emulsion or the like. Preferably, the
14 composition is in the form of a cream, a lotion or a gel. The composition may be
15 directly applied to the body surface. The composition is administered preferably
16 topically. Preferably, the composition may be contained in a patch or bandaging
17 materials.

18 All of the documents or publications recited in the text are incorporated
19 herein by reference.

20 Further details of this invention are illustrated in the following
21 examples.

23 **Example 1**

24 Preparation of a lotion of arsenic trioxide

Compound	Amount	Composition (%)
Arsenic trioxide	0.33 mg	0.033
Stearic acid	9.6 mg	0.96
Cetyl alcohol	7.2 mg	0.72
Anhydrous Lanolin	80 mg	8.0
Vegetable oil	12.8 mg	1.28
Triethanolamine	16 mg	1.6
Water	873.65 mg	87.4
Total	1 g	100

1

2 **Example 2**

3 Preparation of a gel of arsenic trioxide

Compound	Amount	Composition (%)
Arsenic trioxide	2 g	0.05
Carbomer 940	60 g	1.5
PEG	220 g	5.5
Propyl paraben	5 g	0.125
Water	3713 g	92.825
Total	4000 g	100

4

5 **Example 3: Effect of arsenic trioxide on subcutaneous tumors by topical** 6 administration

7 HTB-9 cell line (bladder cancer cell line, purchased from American

8 Type Culture Collection, No. ATCC HTB-9) was cultured in a plate with RPMI

1 (10% FCS) in an incubator at 37°C/5% CO₂. When the cells were grown to a
2 sufficient amount, the cells were treated with trypsin to separate them from the
3 plate, then washed with PBS and diluted to a suitable concentration (2×10⁶
4 cell/50μl). The diluted cells were inoculated subcutaneously near the forelimb or
5 hind legs of 18 BALB/*c-Hfhllnu* female mice (8 weeks old), and tumor growth
6 was recorded.

7 When the tumor was growing after 19 days (the tumor size is about 240
8 mm³), the tested mice were divided into 3 groups (6 mice/group), and arsenic
9 trioxide started to be administrated. The lotion manufactured in example 1 was
10 administered to the first group at the tumor location of the mice. The second
11 group was the control group, and no drugs were administered. The lotion
12 manufactured in example 1 was administered to the third group to the tumor that
13 was incised. The lotion was administrated 3 times per week (Monday,
14 Wednesday and Friday) and 1 drop each time (about 0.14g). The health of those
15 three groups including the survival day and the weight of the mice was recorded.
16 The tumor length, the width and the height were measured, and the volume (mm³)
17 [length (mm) × width (mm) × height (mm)] of the tumor was calculated. With
18 reference to Figs. 1 and 2, treatment of the tumor with the lotion for 80 days
19 obviously suppressed the tumor growth whether the tumor was incised or not.

20
21 Although the invention has been explained in relation to its preferred
22 embodiment, many other possible modifications and variations can be made
23 without departing from the spirit and scope of the invention as hereinafter
24 claimed.